Related Experiment Video
Updated: Aug 23, 2026

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
Published on: April 12, 2021
The effects of hyperlipidaemia on graft and patient outcome in renal transplantation
Domingo Del Castillo1, Josep M Cruzado, Joan Manel Díaz
1Hospital Reina Sofia, Avda. Menendez Pidal 1, 14012 Cordoba, Spain. ddelcastillo@terra.es
Insights
Hypertriglyceridaemia, not high cholesterol, is linked to worse graft survival and cardiovascular mortality in Spanish renal transplant patients. Statins show a protective effect on graft survival.
Area of Science:
- Nephrology
- Transplantation Immunology
- Cardiovascular Medicine
Background:
- Hyperlipidaemia is a common complication post-renal transplantation.
- The impact of high cholesterol and triglycerides on cardiovascular disease and graft survival remains debated.
- Prevalence of hypercholesterolaemia increased in Spanish transplant recipients from 1990-1998, while hypertriglyceridaemia remained stable.
Purpose of the Study:
- To investigate the differential effects of hypercholesterolaemia and hypertriglyceridaemia on graft survival and cardiovascular mortality in renal transplant recipients.
- To identify factors associated with hyperlipidaemia in this population.
- To evaluate the impact of statin therapy on outcomes.
Main Methods:
- Retrospective analysis of renal transplant recipients in Spain.
- Comparison of patient characteristics and treatment regimens between groups with and without hypercholesterolaemia and hypertriglyceridaemia.
- Statistical analysis of risk factors for graft survival and cardiovascular mortality.
Main Results:
- Hypertriglyceridaemia at 3 months post-transplant was associated with worse graft survival (RR 1.078) and increased cardiovascular mortality (RR 1.265).
- Patients with hypertriglyceridaemia often received cyclosporine-based immunosuppression and lipid-lowering agents, and had higher creatinine levels.
- Statin treatment demonstrated a protective effect on graft survival (RR 0.64).
Conclusions:
- Hypertriglyceridaemia, rather than hypercholesterolaemia, poses a significant risk to graft and patient survival in renal transplant recipients.
- Management of hypertriglyceridaemia and the use of statins are crucial for improving outcomes in this patient group.
Abstract:
Hyperlipidaemia is a frequent complication after renal transplantation. As to whether total cholesterol (TC) and triglyceride levels are risk factors for cardiovascular disease and graft survival is controversial. The prevalence of hypercholesterolaemia in the transplanted population in Spain has increased over the years, going from 38.8% in 1990 to 48% in 1998. In contrast, the prevalence of hypertriglyceridaemia being approximately 20%, has not shown any significant variation. Transplant recipients with high cholesterol were characterized by increased age, lower proportion of males, higher mean body mass index, lower proportion of HCV antibodies, reduced time on dialysis and diabetes. Patients with high cholesterol were more frequently treated with cyclosporine + MMF + prednisone and less frequently treated with tacrolimus + MMF + prednisone. Hypertriglyceridaemia was more frequent in patients treated with cyclosporine + MMF + prednisone, and these patients showed significantly higher creatinine plasma levels at 1 year and were more frequently treated with lipid-lowering agents. Hypertriglyceridaemia at 3 months after transplantation is associated with worse graft survival (RR 1.078; CI 1.07-1.143; P = 0.011) and greater cardiovascular mortality (RR 1.265; CI 1.20-1.428; P = 0.0002), while treatment with statins has a protective effect on the graft survival (RR 0.64; CI 0.512-0.888; P = 0.0051). In conclusion, in the renal transplant population in Spain, hypertriglyceridaemia rather than hypercholesterolaemia, may exert a deleterious effect on graft and patient survival.
Related Concept Videos
Kidney Transplant I: Introduction
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Kidney Transplant II: Surgical Procedure
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Kidney Transplant III: Nursing Management
